Vivex Biomedical named Lisa Colleran to succeed Tracy Anderson as Chief Executive Officer. Mr. Anderson, founder of Vivex, will become Vice Chairman and remain on the Board of Directors.
Ms. Colleran is the former CEO of LifeCell, a regenerative medicine company. During her 11-year tenure, LifeCell’s annual revenues grew from US $25MM to ~$200MM. After LifeCell was sold to Allergan in 2017, Ms. Colleran led the company through a second ownership transition, at which point revenue grew to ~$400 million.
Prior to LifeCell, Ms. Colleran spent 20 years at Baxter Healthcare in various commercial and general management roles.
Vivex’s biologic products include demineralized bone matrices and synthetic bone grafts that have application in general orthopaedic, spine and sports medicine procedures.
Vivex Biomedical named Lisa Colleran to succeed Tracy Anderson as Chief Executive Officer. Mr. Anderson, founder of Vivex, will become Vice Chairman and remain on the Board of Directors.
Ms. Colleran is the former CEO of LifeCell, a regenerative medicine company. During her 11-year tenure, LifeCell’s annual revenues grew from US $25MM to...
Vivex Biomedical named Lisa Colleran to succeed Tracy Anderson as Chief Executive Officer. Mr. Anderson, founder of Vivex, will become Vice Chairman and remain on the Board of Directors.
Ms. Colleran is the former CEO of LifeCell, a regenerative medicine company. During her 11-year tenure, LifeCell’s annual revenues grew from US $25MM to ~$200MM. After LifeCell was sold to Allergan in 2017, Ms. Colleran led the company through a second ownership transition, at which point revenue grew to ~$400 million.
Prior to LifeCell, Ms. Colleran spent 20 years at Baxter Healthcare in various commercial and general management roles.
Vivex’s biologic products include demineralized bone matrices and synthetic bone grafts that have application in general orthopaedic, spine and sports medicine procedures.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
